Global review of initial use of triple therapy mass drug administration (IDA) and planning for accelerated elimination of lymphatic filariasis

The objectives of the meeting are to:

1. review the implementation experiences to date of mass drug administration with the new triple therapy regimen, ivermectin, diethylcarbamazine, and albendazole (IDA);

2. discuss best practices for successful introduction of IDA and achieving high coverage;

3. review monitoring and evaluation results to date;

4. develop plans with countries introducing IDA in 2019 & 2020; and

5. facilitate access to donated medicines and diagnostic tests for WHO recommended strategies.